Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NVS-BPTF-1 is a potent and selective small molecule ligand for the bromodomain of Bromodomain and PHD Finger-containing Protein (BPTF). BPTF is a critical scaffolding subunit of the Nucleosome Remodeling Factor (NURF) complex, which regulates gene expression by sliding nucleosomes on DNA. While NVS-BPTF-1 itself often shows limited anti-tumor activity as a standalone inhibitor, it has been utilized as a high-affinity targeting ligand in the development of proteolysis-targeting chimeras (PROTACs). These BPTF degraders have demonstrated therapeutic potential in SWI/SNF-mutant lung cancers, including small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), by disrupting NURF complex stability and chromatin binding.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on NVS-BPTF-1.